Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Genprex, Inc. (GNPX)

Genprex says TROP2 may predict response to REQORSA in lung cancer, data due Nov. 18

Neutral Impact 2 of 5 product/contract Written later

Genprex announced that preclinical and supportive clinical research identifies TROP2 expression as a potential predictive biomarker of response to its lead drug candidate, REQORSA. The poster is scheduled for presentation at the 2026 EORTC-NCI-AACR Symposium in Barcelona, and the company says further research and prospective clinical evaluation are required before TROP2's predictive value is established.

Key points

  • Poster titled TROP2 Predicts Response to TUSC2 Gene Therapy is scheduled for Nov. 18, 2026 in Barcelona, Spain (Abstract 108, Board PB-108).
  • Approximately 50% of 10 NSCLC cell lines and 50% of 12 patient-derived organoid models showed primary resistance to TUSC2 gene delivery.
  • The filing states the findings are preclinical with supportive clinical evidence and that additional research is needed to establish predictive utility.
  • The filing contains no financial results, guidance, or financing terms.

The filing

CompanyGenprex, Inc. (GNPX)
Form8-K, current report
Filed with the SECNov 4, 2026, 7:01 AM ET
Accession number0001437749-26-034764

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.